Cytokinetics And Royalty Pharma Enter Funding Collaboration; Cytokinetics To Receive $50M And Is Eligible To Draw Additional $175M Within 12 Months Of Aficamten Approval, Royalty Will Now Receive 4.5% Up To $5B Of Annual Net Sales Of Aficamten And 1% Above $5B
Portfolio Pulse from Benzinga Newsdesk
Cytokinetics and Royalty Pharma have entered a funding collaboration where Cytokinetics will receive $50 million upfront and is eligible to draw an additional $175 million within 12 months of Aficamten's approval. In return, Royalty Pharma will receive 4.5% of annual net sales of Aficamten up to $5 billion and 1% above $5 billion.
May 22, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cytokinetics will receive $50 million upfront and could draw an additional $175 million within 12 months of Aficamten's approval, providing significant funding for its operations.
The funding collaboration provides immediate financial support and potential future funding, which could positively impact Cytokinetics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Royalty Pharma will receive 4.5% of annual net sales of Aficamten up to $5 billion and 1% above $5 billion, potentially generating significant revenue.
The agreement to receive royalties on Aficamten sales could lead to significant revenue for Royalty Pharma, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100